Free Trial
NASDAQ:ONCY

Oncolytics Biotech (ONCY) Stock Price, News & Analysis

$1.09
+0.03 (+2.83%)
(As of 05/24/2024 ET)
Today's Range
$1.06
$1.11
50-Day Range
$1.00
$1.24
52-Week Range
$0.88
$3.39
Volume
250,852 shs
Average Volume
217,483 shs
Market Capitalization
$82.68 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00

Oncolytics Biotech MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
267.0% Upside
$4.00 Price Target
Short Interest
Healthy
1.14% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.29mentions of Oncolytics Biotech in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.29) to ($0.32) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.96 out of 5 stars

Medical Sector

570th out of 917 stocks

Pharmaceutical Preparations Industry

268th out of 425 stocks

ONCY stock logo

About Oncolytics Biotech Stock (NASDAQ:ONCY)

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

ONCY Stock Price History

ONCY Stock News Headlines

Closing Bell: Oncolytics Bio up on Friday (ONC)
See More Headlines
Receive ONCY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oncolytics Biotech and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/07/2024
Today
5/25/2024
Next Earnings (Estimated)
8/12/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ONCY
Employees
29
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.00
High Stock Price Target
$5.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+267.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-20,560,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.22 per share

Miscellaneous

Free Float
75,777,000
Market Cap
$82.68 million
Optionable
Not Optionable
Beta
1.91
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Dr. Matthew C. Coffey M.B.A.
    Ph.D., President, CEO & Director
  • Mr. Kirk J. Look C.A.
    CA, Chief Financial Officer
  • Dr. Thomas C. Heineman M.D.
    Ph.D., Chief Medical Officer
  • Ms. Allison Hagerman P.Eng.
    P.M.P., Vice President of Product Development
  • Ms. Amy Goodowitz Levin B.S.N.
    R.N., Vice President of Clinical Operations
  • Jon Patton
    Director of Investor Relations & Communication
  • Mr. John Mark Lievonen BBA
    C.M., FCA, LLD, MBA, Consultant

ONCY Stock Analysis - Frequently Asked Questions

Should I buy or sell Oncolytics Biotech stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Oncolytics Biotech in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ONCY shares.
View ONCY analyst ratings
or view top-rated stocks.

What is Oncolytics Biotech's stock price target for 2024?

3 Wall Street research analysts have issued 1 year price objectives for Oncolytics Biotech's shares. Their ONCY share price targets range from $3.00 to $5.00. On average, they predict the company's stock price to reach $4.00 in the next twelve months. This suggests a possible upside of 267.0% from the stock's current price.
View analysts price targets for ONCY
or view top-rated stocks among Wall Street analysts.

How have ONCY shares performed in 2024?

Oncolytics Biotech's stock was trading at $1.35 at the beginning of 2024. Since then, ONCY shares have decreased by 19.3% and is now trading at $1.09.
View the best growth stocks for 2024 here
.

When is Oncolytics Biotech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024.
View our ONCY earnings forecast
.

How were Oncolytics Biotech's earnings last quarter?

Oncolytics Biotech Inc. (NASDAQ:ONCY) released its earnings results on Thursday, March, 7th. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.07.

What is Brad Thompson's approval rating as Oncolytics Biotech's CEO?

2 employees have rated Oncolytics Biotech Chief Executive Officer Brad Thompson on Glassdoor.com. Brad Thompson has an approval rating of 56% among the company's employees. This puts Brad Thompson in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Oncolytics Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oncolytics Biotech investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Bionano Genomics (BNGO), KushCo (KSHB), Organigram (OGI), Pennsylvania Real Estate Investment Trust (PEI), CNBX Pharmaceuticals (CNBX), Zosano Pharma (ZSAN) and DHT (DHT).

Who are Oncolytics Biotech's major shareholders?

Oncolytics Biotech's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Virtu Financial LLC (0.07%).

How do I buy shares of Oncolytics Biotech?

Shares of ONCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ONCY) was last updated on 5/25/2024 by MarketBeat.com Staff

From Our Partners